[Clinical use of photodynamic therapy in gynecologic tumor patients--antibody-targeted photodynamic laser therapy as a new oncologic treatment procedure].
The clinical report addresses the first application of a antibody-targeted photodynamic laser therapy with Phthalocyanines. Photodynamic therapy (PDT) has been proposed as a further treatment modality in oncology. The concept of PDT is based on the interaction between a dye which is accumulated in the target and laserlight. The phototoxic effect is achieved by the augmentation of oxygen radicals. The improvement of the selectivity and the reduction of side-effects is achieved by our concept of using an antibody-targeted phthalocyane induced PDT. The clinical application of the antibody-targeted Phthalocyanine was performed in 3 patients suffering from an advanced ovarian carcinoma (FIGO III). By means of an ultramicroscopical analysis a selective devitalisation of tumor cells was demonstrated. The perspective of PDT reaches far beyond the application for the ovarian carcinomas and relates to all tumor types, where the presence of tumor-associated antigens implicates a treatment in a similar way.
Schmidt
S
S
Universitäts-Frauenklinik, Universität Bonn.
Wagner
U
U
Oehr
P
P
Krebs
D
D
D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use*; D007211:Indoles / Q000008:administration & dosage*; D054833:Isoindoles; D007834:Lasers; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D010053:Ovary / Q000473:pathology; D010778:Photochemotherapy / Q000295:instrumentation*
D000922:Immunotoxins; D007211:Indoles; D054833:Isoindoles; C013647:phthalocyanine
Klinischer Einsatz der photodynamischen Therapie bei gynäkologischen Tumorpatienten--Antikörper-vermittelte photodynamische Lasertherapie als neues onkologisches Behandlungsverfahren.